HENDERSON MICHAEL THOMAS 4
4 · Apogee Therapeutics, Inc. · Filed May 15, 2026
Research Summary
AI-generated summary of this filing
Apogee Therapeutics (APGE) CEO Michael Henderson Sells $1.64M Shares
What Happened
Michael Thomas Henderson, CEO of Apogee Therapeutics, sold a total of 20,000 Apogee shares in open‑market transactions on May 13, 2026, for aggregate proceeds of $1,641,711. The sales consisted of 18,659 shares reported at a weighted average price of $82.05 ($1,530,971) and 1,341 shares reported at a weighted average price of $82.58 ($110,740). These were disposals (transaction code S), not purchases.
Key Details
- Transaction date: May 13, 2026 (reported on Form 4 filed May 15, 2026). Filing appears timely (within the usual 2 business‑day window).
- Trade specifics:
- 18,659 shares @ weighted avg $82.05 → $1,530,971 (footnote F2: actual prices ranged $81.455–$82.440).
- 1,341 shares @ weighted avg $82.58 → $110,740 (footnote F3: actual prices ranged $82.470–$83.265).
- Total: 20,000 shares sold for $1,641,711.
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
- Notable footnotes: F1 — trades executed under a Rule 10b5‑1 trading plan adopted Aug 13, 2025; F2/F3 — reported prices are weighted averages with multiple execution prices (the filer will provide per‑price breakdown on request).
Context
Sales made pursuant to a 10b5‑1 plan are prearranged and often reflect automated or scheduled disposals rather than real‑time trading decisions; they do not necessarily signal a change in the CEO’s view of the company. For retail investors, purchases tend to be more informative than routine sales, but disclosure of such insider sales helps track insider liquidity and timing.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-05-13$82.05/sh−18,659$1,530,971→ 1,117,328 total - Sale
Common Stock
[F1][F3]2026-05-13$82.58/sh−1,341$110,740→ 1,115,987 total
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.455 to $82.440, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.470 to $83.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.